Edesa Biotech Reports Fiscal 1St Quarter 2025 Results
Edesa anticipates topline results could be available within as few as 12 to 18 months following regulatory clearance by the FDA. Health Canada has previously granted approval to initiate this Phase 2 ...
InflaRx launches public offering of shares and warrants
JENA, Germany - InflaRx N.V. (NASDAQ:IFRX), a biopharmaceutical company focusing on anti-inflammatory therapeutics, has initiated a public offering of its ordinary shares along with pre-funded ...
Edesa Biotech secures $15 million for clinical program
TORONTO - Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has announced the completion of a private placement funding round on February 12, 2025, raising approximately ...
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to ...
Parents 'not told of swabs taken from deceased baby'
Ben's parents Allyn and Jenny have said they would not have cremated their son if they knew there were questions over his ...